Suitable for any patient with a solid tumor, the NeXT Dx test is a comprehensive genomics tumor profiling test based on augmented whole exome and transcriptome sequencing.
It works by analyzing the tumor’s genomic and molecular characteristics using clinical-grade, next-generation sequencing (NGS) technology to report small nucleotide variants (SNVs), small insertions and deletions (indels), copy number alterations (CNAs), fusions, MSI and exome-wide “true” TMB. Mutations in certain genes that may be germline in origin are reported as incidental findings. In addition, mutations in genes involved in homologous recombination repair (HRR) are highlighted when identified. A list of genes covered by the NeXT Dx test may be found here.